Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/20/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mary F. Fitzgerald

Wrong Dr. Mary F. Fitzgerald?

Executive Vice President Respirat...

Email: m***@***.com
Company Description: Pulmagen Therapeutics is a privately held respiratory drug development company headquartered in Burnham, Bucks, UK. The company has developed a portfolio of...   more
Background

Employment History

Board Memberships and Affiliations

  • Scientific Advisory Board Member
    Pulmatrix Inc.
  • Board Member
    Argenta/Pulmagen
  • Founding Member
    Etiologics Ltd

Education

  • PhD
20 Total References
Web References
Pulmatrix
www.pulmatrix.com, 20 Nov 2014 [cached]
Mary Fitzgerald, PhD Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. In this position she has had oversight for two Phase II and 3 Phase I studies and has built up a network of leading clinical respiratory consultants including Professor Neil Barnes, Dr Dave Singh and Professor Peter Calverley. Considered one of the world leaders in drug development for COPD and in the preclinical models for respiratory disease, Dr. Fitzgerald has been a Director of Argenta/Pulmagen since October 2004. She has been responsible for clinical development at Argenta and more recently at Pulmagen Therapeutics since 2008. Since 2002, she has also been Director of and is a founding member of Etiologics Limited.
Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She has spent over 20 years conducting research into chronic respiratory disease. She was the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.
Etiologics Limited
www.etiologics.com, 10 Dec 2005 [cached]
Dr Mary F FitzgeraldDirector of Research & Developmentmary.fitzgerald@etiologics.com
Pulmagen Therapeutics | www.pulmagen.com | Oral & Inhaled medicines for chronic lung disease
www.pulmagen.com, 31 Oct 2014 [cached]
Dr Mary Fitzgerald - Executive VP, Respiratory
...
Mary Fitzgerald Formerly Director and Executive VP Respiratory of Argenta Discovery Limited and Director of Etiologics Limited.
Previously with Bayer Healthcare for 14 years, latterly as Head of Pharmacology. Mary has spent over 25 years conducting research and development into drugs for the treatment of respiratory disease.
Domantis
www.mvfund.com, 26 Oct 2005 [cached]
Commenting on the breakthrough, Argenta's Director of Research and Development Dr Mary Fitzgerald, said, "We believe this dAb can become the anti-inflammatory treatment of choice for patients with COPD.
Mary Fitzgerald, Executive ...
www.smi-online.co.uk, 30 Mar 2012 [cached]
Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.
Other People with the name "Fitzgerald":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304